scholarly article | Q13442814 |
P50 | author | Elliott D. Kieff | Q43399614 |
P2093 | author name string | O Devergne | |
G Mosialos | |||
K M Izumi | |||
K M Kaye | |||
E Hatzivassiliou | |||
M F Kleijnen | |||
P2860 | cites work | Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs. | Q35832104 |
Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus | Q35838888 | ||
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines | Q36361402 | ||
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation | Q36575274 | ||
Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation | Q36622140 | ||
Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells | Q36699262 | ||
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23 | Q36806063 | ||
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus | Q36861507 | ||
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity | Q36881880 | ||
Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein | Q36893502 | ||
Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. | Q36904686 | ||
A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection | Q37577729 | ||
Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1. | Q39876882 | ||
Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis | Q41343773 | ||
The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. | Q41371042 | ||
Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. | Q41450017 | ||
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death | Q41678654 | ||
Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40. | Q41727367 | ||
TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation | Q48064873 | ||
A novel RING finger protein interacts with the cytoplasmic domain of CD40 | Q24306382 | ||
A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40 | Q24306620 | ||
Involvement of CRAF1, a relative of TRAF, in CD40 signaling | Q24306746 | ||
A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes | Q24315666 | ||
Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes | Q24315805 | ||
TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways | Q24317441 | ||
A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor | Q24318280 | ||
Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein | Q24599252 | ||
T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors | Q24678367 | ||
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase | Q27860571 | ||
A new technique for the assay of infectivity of human adenovirus 5 DNA | Q27860797 | ||
The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins | Q28117866 | ||
The CD40 antigen and its ligand | Q28286277 | ||
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family | Q28307399 | ||
TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40 | Q28610812 | ||
The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. | Q35831016 | ||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Epstein–Barr virus | Q6900 |
NF-κB | Q411114 | ||
P304 | page(s) | 7098-7108 | |
P577 | publication date | 1996-12-01 | |
P1433 | published in | Molecular and Cellular Biology | Q3319478 |
P1476 | title | Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation | |
P478 | volume | 16 |
Q24291050 | A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains |
Q33759787 | A new domain in the Toll/IL-1R domain-containing adaptor inducing interferon-β factor protein amino terminus is important for tumor necrosis factor-α receptor-associated factor 3 association, protein stabilization and interferon signaling |
Q39736828 | A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein-Barr virus. |
Q39589857 | Activation of lymphocyte signaling by the R1 protein of rhesus monkey rhadinovirus |
Q24683297 | Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein |
Q40951743 | Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production |
Q45752119 | Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts. |
Q39642344 | An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter |
Q33825713 | An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation |
Q34656773 | An Epstein-Barr-related herpesvirus from marmoset lymphomas |
Q77873054 | An aggressive form of polyarticular arthritis in a man with CD154 mutation (X-linked hyper-IgM syndrome) |
Q42937211 | Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site |
Q40790023 | Antisense oligodeoxynucleotides to latent membrane protein 1 induce growth inhibition, apoptosis and Bcl-2 suppression in Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cells, but not in EBV-positive natural killer cell lymphoma cells. |
Q35925874 | Assembly of post-receptor signaling complexes for the tumor necrosis factor receptor superfamily |
Q44605546 | Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. |
Q24298618 | BS69 cooperates with TRAF3 in the regulation of Epstein-Barr virus-derived LMP1/CTAR1-induced NF-kappaB activation |
Q24317586 | BS69 negatively regulates the canonical NF-kappaB activation induced by Epstein-Barr virus-derived LMP1 |
Q36098835 | Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells |
Q40676095 | CD30-governor of memory T cells? |
Q33964729 | CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily |
Q40953967 | CD40- and HLA-DR-mediated cell death pathways share a lot of similarities but differ in their use of ADP-ribosyltransferase activities |
Q34082784 | CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. |
Q22008610 | CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex |
Q28201693 | CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members |
Q40775313 | Caspase-dependent cleavage regulates protein levels of Epstein-Barr virus-derived latent membrane protein 1. |
Q35897193 | Cell transformation by Herpesvirus saimiri |
Q38971933 | Changing patterns in the Epstein-Barr virus (EBV)and Hodgkin lymphoma association in Tunisia |
Q45397749 | Changing patterns in the frequency of Hodgkin lymphoma subtypes and Epstein-Barr virus association in Taiwan |
Q44608902 | Characterization of Epstein-Barr virus (EBV)-positive NK cells isolated from hydroa vacciniforme-like eruptions. |
Q39879963 | Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. |
Q40686720 | Characterization of the Cyno-EBV LMP1 homologue and comparison with LMP1s of EBV and other EBV-like viruses |
Q38427527 | Characterization of the latent membrane protein 1 signaling complex of Epstein-Barr virus in the membrane of mammalian cells with bimolecular fluorescence complementation |
Q38296227 | Characterization of the rapamycin-inducible EBV LMP1 activation system |
Q34061960 | Comparative analysis of the transforming mechanisms of Epstein-Barr virus, Kaposi's sarcoma-associated herpesvirus, and Herpesvirus saimiri |
Q38919438 | Comparison of the peptide binding preferences of three closely related TRAF paralogs: TRAF2, TRAF3, and TRAF5 |
Q93029725 | Constitutive activation of the canonical NF-κB signaling pathway in EBV-associated gastric carcinoma |
Q33813615 | Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. |
Q34234140 | Cytokine signaling and Epstein-Barr virus-mediated cell transformation |
Q35146582 | Death receptors and melanoma resistance to apoptosis |
Q44330153 | Deletions within the epstein-barr virus latent membrane protein-1 oncogene in adult ordinary, HIV-associated and paediatric Hodgkin's disease |
Q37781398 | Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1. |
Q41682745 | Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and Jun N-terminal kinase activation. |
Q36369236 | Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). |
Q39634112 | Dominant expression of survival signals of endoplasmic reticulum stress response in Hodgkin lymphoma |
Q28255713 | Dominant negative mutants of TRAF3 reveal an important role for the coiled coil domains in cell death signaling by the lymphotoxin-beta receptor |
Q36508964 | EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression |
Q93035970 | EBV down-regulates COX-2 expression via TRAF2 and ERK signal pathway in EBV-associated gastric cancer |
Q57186814 | EBV genes and B cell proliferation |
Q30837949 | EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas |
Q36222552 | EBV-Encoded Latent Membrane Protein 1 Cooperates with BAFF/BLyS and APRIL to Induce T Cell-Independent Ig Heavy Chain Class Switching |
Q29618716 | Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice |
Q28207648 | Effects of the NIK aly mutation on NF-kappaB activation by the Epstein-Barr virus latent infection membrane protein, lymphotoxin beta receptor, and CD40 |
Q44519499 | Electroporation-mediated and EBV LMP1-regulated gene therapy in a syngenic mouse tumor model |
Q26859114 | Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder |
Q35609384 | Enhanced Toll-like receptor (TLR) responses of TNFR-associated factor 3 (TRAF3)-deficient B lymphocytes |
Q58803477 | Epstein-Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis |
Q39604074 | Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. |
Q35875444 | Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation |
Q36559750 | Epstein-Barr virus LMP1 modulates lipid raft microdomains and the vimentin cytoskeleton for signal transduction and transformation |
Q27345929 | Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice |
Q35165290 | Epstein-Barr virus down-regulates tumor suppressor DOK1 expression. |
Q30941129 | Epstein-Barr virus encoded latent membrane protein 1 (LMP1) and TNF receptor associated factors (TRAF): colocalisation of LMP1 and TRAF1 in primary EBV infection and in EBV associated Hodgkin lymphoma |
Q28082701 | Epstein-Barr virus latent genes |
Q35121711 | Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation |
Q34789652 | Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. |
Q34721581 | Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNA miR-146a, a modulator of lymphocyte signaling pathways |
Q36845616 | Epstein-Barr virus latent membrane protein 1 represses DNA repair through the PI3K/Akt/FOXO3a pathway in human epithelial cells |
Q34224026 | Epstein-Barr virus latent membrane protein 1: structure and functions |
Q33887684 | Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade |
Q35291650 | Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors |
Q41594644 | Epstein-Barr virus oncogenesis |
Q34313818 | Epstein-Barr virus-associated Hodgkin's lymphoma. |
Q34270437 | Epstein-Barr virus-encoded LMP1 interacts with FGD4 to activate Cdc42 and thereby promote migration of nasopharyngeal carcinoma cells |
Q24516975 | Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2 |
Q40509666 | Epstein-Barr virus-encoded latent membrane protein 1 promotes stress-induced apoptosis upstream of caspase-2-dependent mitochondrial perturbation |
Q33888498 | Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor |
Q36285724 | Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta |
Q41725733 | Epstein-Barr virus: LMP1 masquerades as an active receptor |
Q33797179 | Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. |
Q56917395 | Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells |
Q34089478 | Evolutionary aspects of oncogenic herpesviruses |
Q39544175 | Exosomal sorting of the viral oncoprotein LMP1 is restrained by TRAF2 association at signalling endosomes |
Q40868229 | Expression of the matrix metalloproteinase 9 in Hodgkin's disease is independent of EBV status |
Q38462802 | Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells |
Q40518385 | Expression of tumor necrosis factor receptor-associated factor 1 in nasopharyngeal carcinoma: possible upregulation by Epstein-Barr virus latent membrane protein 1. |
Q40957203 | Functional analysis of different LMP1 proteins isolated from Epstein-Barr virus-positive carriers |
Q48114248 | Functional analysis of the C. elegans cyld-1 gene reveals extensive similarity with its human homolog |
Q34682093 | Generation and characterization of a novel recombinant antibody against LMP1-TES1 of Epstein-Barr virus isolated by phage display |
Q36108705 | HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma |
Q33809963 | Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections |
Q39699142 | Hantavirus pulmonary syndrome-associated hantaviruses contain conserved and functional ITAM signaling elements |
Q35784954 | Herpesvirus saimiri STP-A oncoprotein utilizes Src family protein tyrosine kinase and tumor necrosis factor receptor-associated factors to elicit cellular signal transduction |
Q39579218 | Herpesvirus saimiri transforms human T-cell clones to stable growth without inducing resistance to apoptosis. |
Q37587096 | High molecular weight complex analysis of Epstein-Barr virus Latent Membrane Protein 1 (LMP-1): structural insights into LMP-1's homo-oligomerization and lipid raft association |
Q45722276 | High-resolution methylation analysis and in vivo protein-DNA binding at the promoter of the viral oncogene LMP2A in B cell lines carrying latent Epstein-Barr virus genomes |
Q33297034 | Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel. |
Q34295801 | Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. |
Q24337884 | Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in activation of nuclear factor-kappaB |
Q34479733 | IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation |
Q36984994 | IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3 |
Q28280342 | Identification and functional characterization of DR6, a novel death domain-containing TNF receptor |
Q39595507 | Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus |
Q44022376 | Identification of protein kinase CK2 as a potent kinase of Epstein-Barr virus latent membrane protein 1. |
Q31159325 | Identification of protein kinase inhibitors with a selective negative effect on the viability of Epstein-Barr virus infected B cell lines |
Q24633907 | Identification of transmembrane protein 134 as a novel LMP1-binding protein by using bimolecular fluorescence complementation and an enhanced retroviral mutagen |
Q39594099 | Immortalization of CD4(+) and CD8(+) T lymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone |
Q38168950 | Immunoglobulin class switch recombination deficiency type 1 or CD40 ligand deficiency: from bedside to bench and back again |
Q45660602 | In Hodgkin's disease Reed-Sternberg cells and normal B-lymphocytes are infected by related Epstein-Barr virus strains. |
Q36242117 | Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells |
Q42808155 | Induction of inducible nitric oxide synthase by Epstein-Barr virus B95-8-derived LMP1 in Balb/3T3 cells promotes stress-induced cell death and impairs LMP1-mediated transformation |
Q39410061 | Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells. |
Q45734171 | Inhibition of transforming growth factor beta signaling and Smad-dependent activation of transcription by the Latent Membrane Protein 1 of Epstein-Barr virus |
Q40629419 | Interaction of Epstein-Barr virus latent membrane protein 1 with SCFHOS/beta-TrCP E3 ubiquitin ligase regulates extent of NF-kappaB activation. |
Q33786551 | Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression |
Q33834888 | Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. |
Q33870488 | Intracellular signaling molecules activated by Epstein-Barr virus for induction of interferon regulatory factor 7. |
Q45436282 | LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3. |
Q33890869 | LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2 |
Q81398990 | LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice |
Q34717145 | LMP1 strain variants: biological and molecular properties. |
Q35139273 | LMP1 transmembrane domain 1 and 2 (TM1-2) FWLY mediates intermolecular interactions with TM3-6 to activate NF-kappaB |
Q39777437 | LMP1, a viral relative of the TNF receptor family, signals principally from intracellular compartments |
Q34430225 | LMP1-induced downregulation of CD99 molecules in Hodgkin and Reed-Sternberg cells |
Q79105060 | Latent Membrane Protein 1, Tumor Necrosis Factor Receptor–Associated Factor (TRAF) 1, TRAF-2, TRAF-3, and Nuclear Factor Kappa B Expression in Posttransplantation Lymphoproliferative Disorders |
Q35122447 | Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling |
Q40912121 | Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease |
Q40114217 | Latent membrane protein 1 encoded by Epstein-Barr virus induces telomerase activity via p16INK4A/Rb/E2F1 and JNK signaling pathways |
Q34532370 | Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. |
Q24682515 | Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-kappaB signaling pathway |
Q39593467 | Latent membrane protein 1 of Epstein-Barr virus inhibits as well as stimulates gene expression |
Q33891012 | Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins |
Q34250209 | Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. |
Q40628193 | Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kappa B2 p100 to p52. |
Q43601461 | Latent membrane protein 1-induced EGFR signalling is negatively regulated by TGF alpha prior to neoplasia. |
Q33866046 | Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors |
Q28535439 | Lupeol is one of active components in the extract of Chrysanthemum indicum Linne that inhibits LMP1-induced NF-κB activation |
Q24564927 | Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB |
Q22254016 | MIP-T3, a novel protein linking tumor necrosis factor receptor-associated factor 3 to the microtubule network |
Q36637910 | Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses |
Q37535521 | Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30) |
Q33815241 | Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. |
Q43508237 | Mechanism of action of a novel latent membrane protein-1 dominant negative |
Q92238951 | Modulation of Angiogenic Processes by the Human Gammaherpesviruses, Epstein-Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus |
Q35110891 | Molecular biology of Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus |
Q33835041 | Molecular mechanisms of IgE regulation |
Q40599250 | Molecular mechanisms of the effect of herpesvirus saimiri protein StpC on the signaling pathway leading to NF-kappaB activation |
Q34225554 | Molecular virology of Epstein-Barr virus |
Q36961021 | Multiple roles of TRAF3 signaling in lymphocyte function. |
Q40551263 | Multiple signal transducers and activators of transcription are induced by EBV LMP-1. |
Q36416479 | NF-kappaB activation in melanoma |
Q34225148 | NF-kappaB and cell-cycle regulation: the cyclin connection |
Q40335673 | NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo |
Q28078299 | NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications |
Q34352790 | NF-κB and IRF7 pathway activation by Epstein-Barr virus Latent Membrane Protein 1 |
Q40321857 | NFkappaB signaling is induced by the oncoprotein Tio through direct interaction with TRAF6. |
Q77357711 | Nasopharyngeal carcinoma |
Q24806909 | Natural antisense RNA inhibits the expression of BCMA, a tumour necrosis factor receptor homologue |
Q40549193 | Nuclear factor kappa B (NFkappaB) dependent modulation of Epstein-Barr virus latent membrane protein 1 (LMP1) in epidermal growth factor receptor (EGFR) promoter activity |
Q36961875 | Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. |
Q45753136 | Paediatric Hodgkin's disease in Spain: association with Epstein-Barr virus strains carrying latent membrane protein-1 oncogene deletions and high frequency of dual infections |
Q34292013 | Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. |
Q34584067 | Persistent gamma-herpesvirus infections: what can we learn from an experimental mouse model? |
Q40380273 | Porcine arterivirus activates the NF-kappaB pathway through IkappaB degradation |
Q40985093 | Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. |
Q36944141 | Potential selection of LMP1 variants in nasopharyngeal carcinoma |
Q21134119 | Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes |
Q28114910 | Protein kinase A associates with HA95 and affects transcriptional coactivation by Epstein-Barr virus nuclear proteins |
Q34659176 | Recent advances in the diagnosis and therapy of Richter's syndrome |
Q28137640 | Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase |
Q40742977 | Regulation of TRAF2 signaling by self-induced degradation. |
Q24293065 | Regulation of transactivation function of the aryl hydrocarbon receptor by the Epstein-Barr virus-encoded EBNA-3 protein |
Q36403897 | Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes |
Q43808671 | Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation |
Q34373335 | Richter syndrome: biology, incidence, and therapeutic strategies |
Q36845685 | Role of AID in tumorigenesis |
Q37546963 | Role of Ca2+/calmodulin-dependent kinase II-IRAK1 interaction in LMP1-induced NF-κB activation |
Q33784729 | Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression |
Q45374927 | Roles of TRAF2 and TRAF3 in Epstein-Barr virus latent membrane protein 1-induced alternative NF-kappaB activation |
Q39814540 | Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1 |
Q26853280 | Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions |
Q39968995 | STAP-2 negatively regulates both canonical and noncanonical NF-kappaB activation induced by Epstein-Barr virus-derived latent membrane protein 1. |
Q37693272 | STAT1 and pathogens, not a friendly relationship |
Q45413248 | Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma |
Q57355843 | Signal transduction by the Epstein-Barr virus oncogene latent membrane protein 1 (LMP1) |
Q33822504 | Signaling activities of gammaherpesvirus membrane proteins |
Q33772240 | Simian homologues of human herpesvirus 8 |
Q34992568 | Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation |
Q24292094 | Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling |
Q34374436 | Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas |
Q43472687 | Stimulation of Epstein-Barr virus-infected human B cell growth by physiological concentrations of 4-hydroxynonenal |
Q35078625 | Subversion of B lymphocyte signaling by infectious agents. |
Q41052237 | Synergistic regulation of the human interleukin-12 p40 promoter by NFkappaB and Ets transcription factors in Epstein-Barr virus-transformed B cells and macrophages. |
Q40323227 | TAK1 is a component of the Epstein-Barr virus LMP1 complex and is essential for activation of JNK but not of NF-kappaB. |
Q33864629 | TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs |
Q30578474 | TNF receptor associated factors in cytokine signaling. |
Q41718695 | TRAF binding is required for a distinct subset of in vivo B cell functions of the oncoprotein LMP1. |
Q24338458 | TRAF family proteins link PKR with NF-kappa B activation |
Q36972287 | TRAF molecules in cell signaling and in human diseases |
Q24678181 | TRAF-4 expression in epithelial progenitor cells. Analysis in normal adult, fetal, and tumor tissues |
Q35634395 | TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation |
Q38359234 | TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. |
Q28138885 | TRAF1 is a substrate of caspases activated during tumor necrosis factor receptor-alpha-induced apoptosis |
Q34649278 | TRAF1: lord without a RING. |
Q38801811 | TRAF3 as a powerful and multitalented regulator of lymphocyte functions. |
Q28361340 | TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1 |
Q22253885 | TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation |
Q39578471 | The 30-base-pair deletion in Chinese variants of the Epstein-Barr virus LMP1 gene is not the major effector of functional differences between variant LMP1 genes in human lymphocytes. |
Q33763373 | The EGFR as a target for viral oncoproteins. |
Q34267599 | The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells |
Q35076801 | The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent manner |
Q35997566 | The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation |
Q33882153 | The Epstein-Barr virus and its association with human cancers |
Q34275895 | The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis |
Q34327176 | The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines |
Q24646694 | The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB |
Q34099074 | The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases |
Q24554457 | The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation |
Q40485060 | The Epstein-Barr virus oncoprotein latent membrane protein 1 induces expression of the chemokine IP-10: importance of mRNA half-life regulation |
Q39321358 | The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells |
Q39985447 | The ID proteins contribute to the growth of rodent fibroblasts during LMP1-mediated transformation |
Q38597238 | The Latent Membrane Protein 1 (LMP1). |
Q40893186 | The amino-terminus and membrane-spanning domains of LMP-1 inhibit cell proliferation |
Q77740355 | The antiviral prophylaxis of post-transplant lymphoproliferative disorder |
Q33711382 | The biology of Epstein-Barr virus: lessons learned from the virus and the host |
Q40782239 | The cytoplasmic amino-terminus of the Latent Membrane Protein-1 of Epstein-Barr Virus: relationship between transmembrane orientation and effector functions of the carboxy-terminus and transmembrane domain |
Q34577080 | The effects of the Epstein-Barr virus latent membrane protein 2A on B cell function |
Q34089485 | The expression and function of Epstein-Barr virus encoded latent genes |
Q34384112 | The germinal center kinase TNIK is required for canonical NF-κB and JNK signaling in B-cells by the EBV oncoprotein LMP1 and the CD40 receptor |
Q35850668 | The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation |
Q50064513 | The interactome of EBV LMP1 evaluated by proximity-based BioID approach |
Q39589143 | The late lytic LMP-1 protein of Epstein-Barr virus can negatively regulate LMP-1 signaling |
Q33845947 | The latency-associated nuclear antigen encoded by Kaposi's sarcoma-associated herpesvirus activates two major essential Epstein-Barr virus latent promoters |
Q40061524 | The latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus induces expression of the putative oncogene Bcl-3 through activation of the nuclear factor-kappaB. |
Q34253049 | The latent membrane protein 1 (LMP1) oncogene of Epstein-Barr virus can simultaneously induce and inhibit apoptosis in B cells |
Q40044863 | The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy |
Q35140197 | The molecular basis for the generation of Hodgkin and Reed-Sternberg cells in Hodgkin's lymphoma |
Q35906085 | The multifaceted roles of TRAFs in the regulation of B-cell function. |
Q24674848 | The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2 |
Q39596927 | The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation |
Q33929840 | The role of chemokines in Hodgkin's disease |
Q35145613 | The signaling adaptors and pathways activated by TNF superfamily |
Q35008886 | The significance of LMP1 expression in nasopharyngeal carcinoma |
Q27619945 | The structural basis for the recognition of diverse receptor sequences by TRAF2 |
Q21146664 | The tumor marker Fascin is induced by the Epstein-Barr virus-encoded oncoprotein LMP1 via NF-κB in lymphocytes and contributes to their invasive migration |
Q24685892 | The viral etiology of AIDS-associated malignancies |
Q35192167 | Thermodynamic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry |
Q39787510 | Transcriptional downregulation of p27KIP1 through regulation of E2F function during LMP1-mediated transformation. |
Q40884755 | Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth |
Q28199382 | Tumor necrosis factor receptor-associated factors (TRAFs) |
Q37021555 | Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos |
Q28565703 | Two carboxyl-terminal activation regions of Epstein-Barr virus latent membrane protein 1 activate NF-kappaB through distinct signaling pathways in fibroblast cell lines |
Q24676338 | Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40 |
Q39997624 | Tyrosine Residues Direct the Ubiquitination and Degradation of the NY-1 Hantavirus G1 Cytoplasmic Tail |
Q40714517 | Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia |
Q36098869 | Unique signaling properties of CTAR1 in LMP1-mediated transformation |
Q38303038 | VP4 differentially regulates TRAF2 signaling, disengaging JNK activation while directing NF-kappa B to effect rotavirus-specific cellular responses |
Q40564088 | Vitamin E inhibits cyclosporin A and H2O2 promoted Epstein-Barr virus (EBV) transformation of human B cells as assayed by EBV oncogene LMP1 expression |